World's first paper-based electrochemical DNA biosensor
Portable, table-top device detecting microbial infections and antibiotic resistance genes in under 90 minutes — no culture, no PCR required. Uses patented paper-based electrochemical technology with AI-enabled signal interpretation. Indian patent granted; US patent published at USPTO.
Clinical panels validated
MedTech startup focused on rapid infection diagnostics and antimicrobial resistance detection using paper-based DNA biosensor technology.
RAMJA Genosensor Pvt. Ltd. represents a significant milestone in India’s diagnostic innovation journey. It is fast-growing MedTech startup focused on rapid infection diagnostics and antimicrobial resistance (AMR) detection using innovative paper-based DNA biosensor technology.
The startup has developed rapid, portable, and cost-effective diagnostic solutions that can detect infections and AMR within 90 minutes. RAMJA Genosensor Won >50 Indian and International awards worth rupees >4 crore.
Ramja Genosensor is CDSCO and ISO-13485-2016 approved first IVD device and Manufacture in molecular platform .The RAMJA Genosensor aims to reduce diagnostic delays and support timely antibiotic treatment across hospitals, laboratories, and remote healthcare centers in India.
With innovations like PRATHAMASENSE and multiple infection detection panels, Ramja Genosensor is expanding its presence across India and contributing to the fight against antibiotic resistance and healthcare-associated infections.
Add your company logo, name, and a short description — this is what visitors see first.
Your tagline goes here
List up to 3 key offerings visible to visitors
e.g. "Diagnostic kits · Lab equipment · AMR solutions"
Add a direct link and a call-to-action label — users click and land on your platform instantly.
A single platform can process blood, urine, tracheal aspirates, sputum, and other biological fluids with ease.
The technology enables rapid processing of large sample volumes with minimal workflow complexity.
PRATHAMASENSE operates with basic infrastructure including a centrifuge, incubator, and standard biosafety setup.
B.Sc., BMLT, and laboratory technicians can operate the system efficiently after one week of training.
The platform offers PDF ready report, with ICMR Recommended guideline, cloud-enabled real-time reporting, centralized monitoring, and instant clinical data access.
The system can function in peripheral healthcare centres with 24×7 power backup compatibility.
Early diagnosis supports reduced ICU stay, faster patient discharge, and improved hospital revenue.
Rapid pathogen and AMR detection promotes evidence-based antibiotic usage and reduces antimicrobial resistance.
The platform is scalable for deployment across tertiary hospitals, government programs, and peripheral diagnostic centers.
Fill in your details and the MITHRIL® Splints team will arrange a demo at your convenience.
Fill in your details and the MITHRIL® Splints team will arrange a demo at your convenience.
